Therapeutic antibodies: successes, limitations and hopes for the future
By P. Chames, M. H. V. Van Regenmortel, Etienne Weiss, D. Baty. British Journal of Pharmacology, 2009
1,366 citations recorded by the source corpus.
With more than 20 molecules in clinical use, monoclonal antibodies have finally come of age as therapeutics, generating a market value of $11 billion in 2004, expected to reach $26 billion by 2010. While delivering interesting results in the treatment of several major diseases including autoimmune, cardiovascular and infectious diseases, cancer and inflammation, clinical trials and research are generating a wealth of useful information, for instance about associations of clinical responses with Fc receptor polymorphisms and the infiltration and recruitment of effector cells into targeted tissues. Some functional limitations of therapeutic antibodies have come to light such as inadequate pharmacokinetics and tissue accessibility as well as impaired interactions with the immune system, and these deficiencies point to areas where additional research is needed. This review aims at giving an overview of the current state of the art and describes the most promising avenues that are being followed to create the next generation of antibody‐based therapeutic agents.
Subfields: Immunology, Molecular Biology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/1c17b29e63649d39046bd9b96aa2cf8c6fe0e9cd
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Molecular Biology
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- Antibody Structure and Function: The Basis for Engineering Therapeutics (2019, background): “Other modifications to enhance ADCC include the introduction of bisecting N acetyl glucosamine and the removal of sialic acid residues [420].”
- A new anti-mesothelin antibody targets selectively the membrane-associated form (2017, background): “The use of monoclonal antibodies (mAbs) against membrane targets has been shown to increase the survival of patients having several cancers.(15) Several antibody-based molecules that target mesothelin have been developed.”
- Naïve Human Antibody Libraries for Infectious Diseases (2018, background): “Conversion of antibody fragments into full IgG format or Fc format is always preferable for therapeutics [171] .”